



Barbara Lim
ASX Limited
Level 40, 152-158 St Georges Terrace
PERTH WA 6000

18 November 2025

Tryptamine Therapeutics Limited - Secondary Trading Notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth)

This notice is given by Tryptamine Therapeutics Limited (ASX: TYP) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Act) in compliance with the requirements of section 708A(6). Tryptamine Therapeutics Limited confirms that:

- (a) it issued 165,588,237 fully paid ordinary shares at an issue price of \$0.034 per share on 18 November 2025 without disclosure to investors under part 6D.2 of the Act;
- (b) this notice is being given under 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this notice, there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act.

This announcement has been authorised by the Board of Tryptamine Therapeutics Limited.

Kind regards

A handwritten signature in black ink, appearing to read 'Hamish George'.

Hamish George
Company Secretary & CFO
Tryptamine Therapeutics Ltd